VEGF signalling inhibitors as biomarkers 210
Biomarkers of prognosis in cancer treatment 210
Biomarkers of drug resistance in cancer 210
A systems approach to biomarkers of innate drug resistance 211
Epithelial membrane protein-1 as a biomarker of gefitinib resistance 211
Methylation biomarkers of drug resistance in cancer 211
Biomarkers of radiation exposure 212
Role of biomarkers in drug development in oncology 212
Molecular imaging of tumor as a guide to drug development 213
Use of PET to assess response to anticancer drugs 213
Use of MRI to assess response to anticancer drugs 214
Biomarkers in plucked hair for assessing cancer therapy 214
Molecular targets of anticancer drugs as biomarkers 214
Safety biomarkers in oncology studies 215
Role of biomarkers in phase I clinical trials of anticancer drugs 215
Biomarkers according to location/type of cancer 215
Bladder cancer biomarkers 215
Detection of FGFR3 mutations in urine for diagnosis of bladder cancer 216
NMP22 BladderChek 216
Urinary telomerase as biomarker for detection of bladder cancer 216
Concluding remarks abut biomarkers of urinary cancer 216
Brain cancer biomarkers 217
Biomarkers to predict response to EGFR inhibitors 217
CD133 as biomarker of resistance to radiotherapy 218
Circulating microvesicles as biomarkers 218
CSF protein profiling 218
CSF attractin as a biomarker of malignant astrocytoma 218
Methylation profiling of brain tumors 219
Metabolite biomarkers of brain tumors 220
miRNAs as biomarkers of brain tumors 220
MRI biomarker for response of brain tumor to therapy 220
Multigene predictor of outcome in GBM 221
Neuroimaging biomarkers combined with DNA microarray analysis 221
Receptor protein tyrosine phosphatase ? as biomarker of gliomas 221
Se
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |